---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004734"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:19:51.432318+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Announces Preclinical Data and 2023 Strategic Priorities at J.P. Morgan Healthcare Conference

## Summary
- New preclinical data in Friedrich's ataxia and cystic fibrosis show restoration of genetic function via Prime Editing.
- Preliminary off-target safety analyses in Wilson's disease and CGD detected no guide-dependent editing across 170 and 550 sites, respectively.
- PASSIGE technology achieved ~60% precise insertion of a 3.5 kb transgene into primary human T cells in a one-step non-viral process.
- LNP delivery to rodent liver achieved >40% editing of PCSK9 gene and >90% reduction in serum PCSK9 protein.
- Company expects to nominate first development candidate for CGD in Q1 2023 and file first IND as early as 2024.

## SEC filing metadata
- accession: 0001193125-23-004734
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000119312523004734/0001193125-23-004734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000119312523004734/d448162d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004734
- JSON: https://secwatch.observer/filing/0001193125-23-004734.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004734.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.